Novo Nordisk Flags Sales Decline Amid Pricing Pressures, GLP-1 Market Maturation

Event summary

  • Novo Nordisk exceeded 2025 sales and operating profit guidance, reporting 10% and 6% growth respectively.
  • The company anticipates a USD 4.2 billion reversal of sales rebate provisions related to the 340B Drug Pricing Program in 2026.
  • Novo Nordisk is introducing adjusted sales and operating profit measures to exclude non-recurring items, projecting a -5% to -13% decline in both for 2026.
  • The company expects sales decline in US Operations, offset by growth in International Operations, driven by GLP-1 market expansion but tempered by pricing pressures and competition.

The big picture

Novo Nordisk's revised outlook signals a shift in the GLP-1 market, moving from a period of rapid expansion to one characterized by pricing pressure and increased competition. The company's decision to introduce adjusted profit metrics highlights the complexity of accounting for one-time gains and losses, and underscores the challenges of maintaining growth in a maturing market. The reversal of sales rebate provisions, while providing a short-term boost, also underscores the ongoing impact of US drug pricing regulations.

What we're watching

Pricing Dynamics
The sustainability of the MFN agreement with the US Administration and its impact on Novo Nordisk's pricing power will be crucial to monitor, potentially impacting future revenue streams.
GLP-1 Competition
The intensifying competition within the GLP-1 market, particularly as semaglutide loses exclusivity, will likely continue to erode Novo Nordisk's market share and necessitate further innovation.
US Coverage
The extent to which reduced obesity medication coverage in Medicaid affects Novo Nordisk's US sales and the effectiveness of NovoCare® Pharmacy in mitigating this impact warrants close observation.

Related topics

Pharmaceuticals